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Re: The role of hospice care at the end of life for people with cancer 
JCO.18.02235R2 
Thank you for the opportunity to respond to the helpful and constructive comments of Reviewer #2 for this 
paper. The comments are addressed in the order in which they appear on a point-by-point basis.  
 Reviewers’ comments Authors’ responses 
Reviewer #2 
 1. Please add the citation number after 
Steinhauser et al. on page 4. 
The citation number has been added after the 
first sentence.  
 2. The manuscript describes treatment 
options for breathlessness (page 5) but not 
fatigue (page 5). Consider adding text briefly 
describing treatment options or management 
strategies for fatigue near the end of life. 
This omission has been rectified. The most 
recent Cochrane review is now cited and its 
findings reflected in the manuscript.  
 3. Please remove parentheses around the 
statement on page 9 beginning, "There is a 
current generation…". 
The parentheses have been removed as 
suggested.  
 4. Consider adding text in the manuscript on 
page 9 identifying the palliative care needs 
assessment tool that is the focus of reference 
62. 
Text has been added outlining the name of the 
tool and its overall structure.  
 5. There would appear to a typo in the text in 
parentheses at the bottom of page 10 
describing the percentages of patients with 
and without hospice access who used the ED. 
Thank you. The sentence now reads ‘…used the 
ED while it increased to 52.0% of people…’ 
 6. Please edit for clarity the sentence on page 
12 that begins, "One observational study…". 
There would appear to be multiple typos 
present. 
This sentence has been rewritten to improve 
clarity.  
 7. There would appear to be word missing 
after "phase III on page 
The word ‘studies’ has been added.  
 
Attached is a clean copy of the manuscript and a version with track changes. Thank you once again for the 
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If there are any issues that I can clarify, please do not hesitate to contact me.  
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Patient-defined factors that are important at the end of life include being physically 
independent for as long as possible, good symptom control and spending quality time with 
friends and family. Hospice care adds to the quality of care and these patient-centered 
priorities for people with cancer and their families in the last weeks and days of life. 
Evidence from large observational studies demonstrate that hospice care can directly improve 
outcomes, and support better and more appropriate health care utilization for people in the 
last stages of cancer.  
Team-based community hospice care has measurable benefits for patients, their family 
caregivers and health services. In addition to improved symptom control for patients and 
greater likelihood of time spent at home, caregiver outcomes are also better when hospice 
care is accessed: informational needs are better met and caregivers have an improved ability 
to move on with life after the patient’s death when compared to people who did not have 
access to these services. 
Hospice care continues to evolve as its reach expands, and the needs of patients continue to 
broaden. This is reflected in the transition from hospice being based on excellence in nursing 
to teams with a broad range of health professionals to meet the complex and changing needs 
of patients and their families. Further integration of cancer services with hospice care will 
help to provide more seamless care for patients and supporting family caregivers during their 
caregiving and after the death of the patient.   
 





How can hospice care best add value to the quality of care and outcomes for patients and 
their families as they live with advanced cancer?  
Given differences in how the terms ‘palliative care’ ‘hospice’ are used around the world, in 
this article the definitions reflect care provision in the United States of America where: 
‘palliative care’ refers to a range of services offered through close and ongoing 
integration of care for anyone with a life-limiting illness, ideally from the time that a 
life-limiting illness is recognised. High quality evidence from randomised trials and 
large observational studies support early access for people with advanced cancer;1-5 
and 
 ‘hospice’ refers to community-based care that is offered, ideally, by a multi-
disciplinary team that supports patients with advanced diseases and their families. In 
the USA, this type of care is funded per diem by the Medicare Hospice benefit and is 
available to people who have less than six months to live. 
Palliative care is dealt with in other articles in this issue and, although philosophically and 
practically palliative care and hospice have some overlap, this article focuses on hospice care. 
Likewise the taxonomy of ‘end of life’ differs globally and in this article it will refer to the 
last weeks or days of people’s lives.   
Ideally, palliative care will have been introduced earlier in the disease trajectory for people 
with advanced cancer, as this is likely to increase the proportion of people referred earlier to 
hospice care.6 Even if earlier referral to palliative care has not happened, congruent with 
emerging health services evidence,7,8 hospice care at the end of life is crucial if outcomes are 
to be optimised for patients and for their caregivers (while caring and after the person’s 
death). Such care reflects the expressed wishes of communities9 to prioritise care for people 
at the end of life in the setting of their choice wherever possible and to the highest standard 
that evidence-based practice enables. 
Patient-defined priorities at the end of life 
In order to determine the benefits that hospice care can deliver, patients with advanced cancer 
need to determine the priorities. These voices are heard in the seminal study by Steinhauser et 
al.10 The team ran focus groups with patients to define issues deemed important at the end of 
life which were then transformed into survey questions for random samples in the USA from: 
a Veteran’s population who were aware they had limited prognoses and caregivers 6-12 
months after their caregiving was completed; and health professionals (not limited to 
Veterans Affairs): physicians who provided care for people with life-limiting illnesses as part 
of their practice; and nurses and allied health professionals.10 Key priorities identified by all 
groups included: excellence in pain and other symptom control (not as an end in itself but in 
order to optimise wellbeing and physical independence for as long as possible); to be well 
enough to spend as much quality time with friends and family; deal with unfinished business; 
and finalise any legacy issues. These priorities have been affirmed in several other studies of 
people with advanced, progressive cancers.11-19 In the Steinhauser study, there were also 
occasions where patients’ priorities differed from other respondents’. The place of care at the 
time of death was not a high priority for patients, perhaps reflecting the complexity of 
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decisions around this, especially if there are tensions between patients and their family 
caregivers.20 Health professionals providing care in the last weeks of life need to constantly 
re-explore the patient’s preferred place of care and the caregivers’ willingness and capacity to 
provide that care, especially if symptoms worsen or as physical function declines.21  
Reflecting these patient- and caregiver-defined priorities, hospice care services have grown 
rapidly to support families and communities to care for people at home (including in skilled 
nursing facilities) through excellence in physical symptom control, psychological support, 
spiritual care and support for caregivers.  
Symptom burden in end-of-life care 
Hospice care improves symptom control in problems prevalent at the end of life.22 Attention 
to physical symptoms is valued by patients and their families as a key goal of care. 10 There is 
a rapidly evolving evidence base from randomised controlled trials to improve symptom 
control in end of life care 23-26 yet many of these findings have not been embedded in 
practice.14 The research also highlights areas where further research is necessary.  
The burden of physical symptoms evolves in the last weeks of life. Two symptoms which 
tend to worsen as functional status predictably declines are fatigue and breathlessness.27,28 
Fatigue not reduced by rest is often the most overwhelming symptom experienced by people 
with advance cancer. It often co-exists with cachexia in this setting.29 Fatigue generates 
frustration for patients as they struggle to re-prioritise their activities in the limited time that 
they have left, while often being exhausted by relatively trivial exertion. Non-
pharmacological interventions have not been well studied in people in the last weeks of life.30  
Other than reversing causes that can cause fatigue (severe anaemia), the evidence for 
pharmacological interventions for fatigue in patients with advanced cancer is limited.31  
Candidate medications include methylphenidate, amantadine or modafinil, but none has 
sufficient data to justify their use in routine clinical care.  
Prevalence and intensity of chronic breathlessness32 often worsen as death approaches even in 
people with no documented cardio-respiratory disease, especially in the last two to three 
weeks of life.33 The proportion of people with no breathlessness drops rapidly in the last 
weeks of life and the proportion with severe breathlessness increases despite symptomatic 
treatment. The evidence base for effectively and safely treating chronic breathlessness 
continues to improve using non-pharmacological and pharmacological interventions reflected 
in systematic reviews and meta-analyses.34,35 In a systematic approach to assessing and 
treating chronic breathlessness akin to the World Health Organisation (WHO) analgesic 
ladder, the most important step is to ensure that reversible causes have been adequately 
treated36 while considering non-pharmacological and subsequently pharmacological 
interventions.37 Uncontrolled breathlessness is frightening and exhausting for patients, and 
confronting for caregivers, often leaving haunting and unpleasant memories.38 Minimising  
breathlessness is therefore imperative for patients’ and families’ wellbeing.  
As function declines in the last weeks of life, the intensity and prevalence of pain may also 
decrease, perhaps reflecting how much of the pain is exacerbated with incident movement 
and subsequently experienced at rest.39 Good analgesia is often the priority for patients and 
their families above any other symptom right through until death. Evidence supports that 
hospice care provides better analgesia for patients when compared to patients who did not 
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access hospice.22 Late in life, immobility perversely also frequently causes pain and careful 
attention to repositioning patients regularly is a hallmark of exemplary nursing care. When 
patients no longer have the strength to reposition themselves, air mattresses can help to shift 
patients’ weight but do not replace ongoing attentive nursing care. 
Delirium is characterised by cognitive changes (especially poor concentration), perceptual 
changes (especially hallucinations) and physical changes such as disturbed sleep/wake cycles. 
One third of people admitted for inpatient care at the end of life will have prevalent delirium 
and another one third will develop incident delirium during the admission,40 encompassing  
hypoactive and hyperactive delirium. Hypoactive delirium is under-diagnosed in people at the 
end of life, but can be as distressing for patients as hyperactive delirium.  
In a percentage of patients, reversible causes for delirium will be found, aiding them to more 
rapidly regain their cognition.41,42 The first aim of managing delirium is to ensure patient 
safety, and the safety of all those around the patient. Excellent nursing care ensures that 
visual and hearing aids are in place, ongoing efforts are made to orient the person, day and 
night are differentiated, and that hydration and nutrition are attended to with regular meals 
where feeding is supervised.  
Benefits from anti-psychotics for delirium seem negligible in placebo controlled studies 
involving intensive care patients and those nearing the end of life.25,43 Delirium requires 
excellent nursing care, treating reversible precipitants and, if there is a need for safety, 
consideration of a sedative short term.  
Symptoms in the last hours of life 
For many caregivers, the person’s last hours will be remembered because of noisy respiratory 
secretions. This noise is because secretions are not being cleared effectively and is usually 
associated with the patient being deeply unconscious. The treatment of these secretions is 
largely, if not exclusively, for the benefit of the person’s family. There is no demonstrated 
intervention for preventing noisy secretions at the end of life and no pharmacological or non-
pharmacological intervention that has been shown to be of predictable benefit in changing the 
clinical course of secretions.43 
Patients rating of symptom control – the need to improve care 
There is international evidence that the quality of care for people with advanced, progressive 
illnesses must improve.15-19,45 Feedback that is independent of the individual health care 
professional/patient interaction suggests that symptom control is not as good as we anticipate, 
nor as good as patient and families expect.17,19 This reflects an under-detection by clinicians, 
clinical interventions which do not reflect best evidence, and lack of referral to inter-
disciplinary services that could provide more comprehensive support for people with more 
complex needs. 
Addressing this mismatch includes critically evaluating the quality of care for people with 
cancer at the end of life.46-50 Providing timely feedback from patients and their caregivers to 
their clinicians can contribute to improved symptom control.49,50 For example, patients filling 
out a symptom assessment tool immediately before clinical consultations so that clinicians 
see the results improves symptom control and is associated with better survival.51 Given the 
value placed on symptom control by patients and their caregivers, and the symptom burden 
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experienced by people with cancer at the end of life, health professionals need to ensure that 
the best available evidence underpins all clinical care. 
Hospice care 
Given the emphasis on excellent nursing care for optimal outcomes at the end of life, it is 
appropriate that hospice care has arisen from nursing and been complemented with other 
clinical disciplines more recently. Care that can support patients to be functional for as long 
as possible and simultaneously provide symptom control will deliver the best outcomes. The 
majority of care in the last year of life occurs in the community 52 and relies almost 
exclusively on the presence, capability and willingness of family and friends to take on 
caregiving roles.53 The way that caregivers are supported in their new roles is a fundamental 
of hospice care.  
When people with advanced cancer start to experience rapid functional declines, it is 
important to ensure hospice care is in place. At this time, conversations about prognosis 
should occur. The speed of deterioration in the last weeks of life is surprising to many 
clinicians who do not frequently encounter it.54 Providing realistic timeframes to patients and 
their caregivers is an important part of care in the last weeks of life. Patients need this 
information so that they are able to prioritise the things that are most important to them in the 
time remaining. 
Key competencies for all health professionals in end of life care.  
Several competencies are required for good end-of-life care. Every health professional ought 
to be able to demonstrate core end-of-life competencies including: recognising the end-of-
life; understanding of the principles of symptom control and inter-disciplinary care; patient-
centred communication and shared decision making; clinical skills in thorough bedside 
assessment; and fostering personal attributes including empathy and compassion.55 Good 
communication includes active listening, responding to emotion, communicating difficult 
information, and ascertaining the person’s values and preferences (especially for advance 
care planning). These capabilities enable health professionals to help patients and their 
families plan their end-of-life care, manage concerns and foster good interdisciplinary care. 
There is a current generation of health professionals for whom hospice care was not part of 
their training, and for whom a specific commitment will need to be made to improve 
knowledge and skills56 - a challenge once in busy practice.57 
Key competencies for specialist hospice care clinicians 
To complement the general clinical workforce, there is the need to have a specialist 
hospice/palliative care workforce that can provide care to patients and families with more 
complex needs. Whilst providing this more complex care, this specialist workforce is 
simultaneously continuing to generate new evidence (research) and rapidly translate it into 
practice to improve care (education, systems change).24,25,58-61 Studies demonstrate that when 
high quality evidence is generated, health professionals change practice.62,63   
Team-based care 
Good support provided to patients and their families is intrinsically complex. It is unlikely 
that any one clinician will meet the entire hospice care needs of each patient and their family 
while the person is alive or the family’s needs after the person’s death.  Using a validated 
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palliative care needs assessment tool helps clinicians recognise when the patients or families 
require additional support from other team members or services.64 The Palliative Care Needs 
Assessment Tool (Cancer) (PC-NAT (Cancer)) has four domains: patient; caregiver 
willingness to provide care; caregiver ability to provide care; and any health professional 
issues.65 The routine use of such a tool in people with advanced cancer in an interrupted time 
series study compared to standard practice demonstrated better met informational needs for 
patients and caregivers.21 Evidence for the validity of this tool in primary care consultations 
in people with advanced cancer has been established.66  
An inter-disciplinary team approach is needed to provide patients and their families with a 
range of health professionals with whom to interact. The ability to relate to a broader group 
of people allows patients and their families to choose when and what is discussed and with 
whom. It is likely that patients will discuss different issues with different health professionals 
in the time and place that suits the patient. This means that several lines of communication 
need to be open to people in the last weeks of life.  
Given the advances that are being made in high quality evidence, it is unlikely that any one 
practitioner can be fully up to date, thus requiring a team-based, interdisciplinary approach. 
Given the breadth of patient-defined needs at the end of life, several health professionals 
working collaboratively will be essential to achieve the best possible patient outcomes.  
Interfaces between hospice and other healthcare settings 
Most people will use hospitals in the last year of life, increasing markedly in the final months 
of life 52 and in most high income countries the majority of people who die from cancer will 
do so as an inpatient. This requires an effective working relationship between hospice and 
other health services. Planning of care reduces hospitalisations and emergency department 
presentations. 67,68 In a retrospective consecutive cohort study of 91,561 people with 
advanced cancer in Canada, on average, people made more than two visits to the Emergency 
Department (ED) in the last six months of life, mostly due to poor symptom control.69 In a 
retrospective consecutive cohort study of 746 people with advanced cancer, timely referral to 
hospice was associated with reduced use of the ED by people with advanced cancer (31.3% 
of people who had earlier access to hospice used the ED while it increased to 52.0% of 
people who didn’t have hospice access), fewer hospital bed days and better symptom 
control.70 These findings are reflected in a more recent retrospective study from 54,743 
people with advanced cancer where access to hospice care in the last six months of life 
reduced high- and low-acuity ED presentations.71 Reduced costs without compromising care 
can be demonstrated,67,68,72 although this cost-benefit was less clear after the hospice benefit 
payment was extended to nursing homes in the USA.73 Differentials in hospital utilisation and 
use of intensive care is a key driver in any measured cost differentials.74,75 
A dynamic and timely interface between hospice providers and inpatient services is 
increasingly being facilitated by the use of electronic information technology clinical 
platforms, ensuring better currency of clinical data as people move between places of care. 
Ensuring that both clinical teams are aware of each other’s conversations with the patient and 
family is a fundamental challenge that persists even in an era with improving electronic 
records. 
Inpatient hospice care may be the preferred choice by patients and their families when: 
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- symptoms are complex or not responding to current therapies where a brief inpatient 
admission may more rapidly bring symptoms under control;76 
- An unexpected change in clinical condition when the person had a reasonable level of 
function and wants to pursue reasonable efforts to reverse treatable pathology;  
- Care needs exceed available community services especially due to caregiver fatigue;77 
or 
- The person in the last days or hours of life does not want to die at home.20,78   
A growing number of people live alone in our communities and is projected to rise in the 
decades ahead. The ability of someone with advanced cancer to remain at home if they live 
alone until the time of their death is very limited. If a person’s preference is to die at home, 
the greatest predictor of this occurring is the presence of a willing and able caregiver.53 
Specific issues arise in advance care planning for people without a live-in caregiver that need 
to be addressed expectantly.  
Caregiver outcomes 
Few data are available for long term caregiver outcomes with and without access to hospice. 
One large observational study comparing cohorts who did and did not access hospice care 
suggests two benefits for caregivers: informational needs were better met; and the caregiver 
had a greater ability to ‘move on’ with his/her life after the patient’s death.79 A cause-and-
effect relationship cannot be inferred, but the study provides supportive evidence from a 
randomly selected community population who identified that they had provided care for 
someone close to them with a terminal illness in the preceding five years. Studies using 
propensity matched scores for caregivers who did and did not access hospice have shown 
associations including improved survival and lower rates of depression.80 Such data 
complement data on patient-related measures such as improved symptom control.10,81    
Conclusion 
Clinically, data support ensuring patients have the option to consider hospice as a clinical 
path when it is recognised that they have advanced cancer. Hospice provides patients with the 
potential for better quality of life, improved symptom control, and more time away from 
inpatient care.2 The majority of care falls to family and friends, and any additional support for 
them while fulfilling their role is likely to be of substantial benefit. Observational studies 
suggest measurable benefits for caregivers after the patient dies.79,80,81 For health services, 
data support that health service utilisation is more likely to be clinically appropriate with 
fewer hospital visits, shorter lengths of stay and less time in intensive care units if hospice is 
engaged.2,7,8,53,67,74 The future research agenda needs to include larger health service 
randomised controlled trials to fully define the net effects (benefits and burdens) of hospice 
together with larger phase III studies in key symptoms where the therapeutic choices are still 
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Patient-defined factors that are important at the end of life include being physically 
independent for as long as possible, good symptom control and spending quality time with 
friends and family. Hospice care adds to the quality of care and these patient-centered 
priorities for people with cancer and their families in the last weeks and days of life. 
Evidence from large observational studies demonstrate that hospice care can directly improve 
outcomes, and support better and more appropriate health care utilization for people in the 
last stages of cancer.  
Team-based community hospice care has measurable benefits for patients, their family 
caregivers and health services. In addition to improved symptom control for patients and 
greater likelihood of time spent at home, caregiver outcomes are also better when hospice 
care is accessed: informational needs are better met and caregivers have an improved ability 
to move on with life after the patient’s death when compared to people who did not have 
access to these services. 
Hospice care continues to evolve as its reach expands, and the needs of patients continue to 
broaden. This is reflected in the transition from hospice being based on excellence in nursing 
to teams with a broad range of health professionals to meet the complex and changing needs 
of patients and their families. Further integration of cancer services with hospice care will 
help to provide more seamless care for patients and supporting family caregivers during their 
caregiving and after the death of the patient.   
 





How can hospice care best add value to the quality of care and outcomes for patients and 
their families as they live with advanced cancer?  
Given differences in how the terms ‘palliative care’ ‘hospice’ are used around the world, in 
this article the definitions reflect care provision in the United States of America where: 
‘palliative care’ refers to a range of services offered through close and ongoing 
integration of care for anyone with a life-limiting illness, ideally from the time that a 
life-limiting illness is recognised. High quality evidence from randomised trials and 
large observational studies support early access for people with advanced cancer;1-5 
and 
 ‘hospice’ refers to community-based care that is offered, ideally, by a multi-
disciplinary team that supports patients with advanced diseases and their families. In 
the USA, this type of care is funded per diem by the Medicare Hospice benefit and is 
available to people who have less than six months to live. 
Palliative care is dealt with in other articles in this issue and, although philosophically and 
practically palliative care and hospice have some overlap, this article focuses on hospice care. 
Likewise the taxonomy of ‘end of life’ differs globally and in this article it will refer to the 
last weeks or days of people’s lives.   
Ideally, palliative care will have been introduced earlier in the disease trajectory for people 
with advanced cancer, as this is likely to increase the proportion of people referred earlier to 
hospice care.6 Even if earlier referral to palliative care has not happened, congruent with 
emerging health services evidence,7,8 hospice care at the end of life is crucial if outcomes are 
to be optimised for patients and for their caregivers (while caring and after the person’s 
death). Such care reflects the expressed wishes of communities9 to prioritise care for people 
at the end of life in the setting of their choice wherever possible and to the highest standard 
that evidence-based practice enables. 
Patient-defined priorities at the end of life 
In order to determine the benefits that hospice care can deliver, patients with advanced cancer 
need to determine the priorities. These voices are heard in the seminal study by Steinhauser et 
al.10 The team ran focus groups with patients to define issues deemed important at the end of 
life which were then transformed into survey questions for random samples in the USA from: 
a Veteran’s population who were aware they had limited prognoses and caregivers 6-12 
months after their caregiving was completed; and health professionals (not limited to 
Veterans Affairs): physicians who provided care for people with life-limiting illnesses as part 
of their practice; and nurses and allied health professionals.10 Key priorities identified by all 
groups included: excellence in pain and other symptom control (not as an end in itself but in 
order to optimise wellbeing and physical independence for as long as possible); to be well 
enough to spend as much quality time with friends and family; deal with unfinished business; 
and finalise any legacy issues. These priorities have been affirmed in several other studies of 
people with advanced, progressive cancers.11-19 In the Steinhauser study, there were also 
occasions where patients’ priorities differed from other respondents’. The place of care at the 
time of death was not a high priority for patients, perhaps reflecting the complexity of 
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decisions around this, especially if there are tensions between patients and their family 
caregivers.20 Health professionals providing care in the last weeks of life need to constantly 
re-explore the patient’s preferred place of care and the caregivers’ willingness and capacity to 
provide that care, especially if symptoms worsen or as physical function declines.21  
Reflecting these patient- and caregiver-defined priorities, hospice care services have grown 
rapidly to support families and communities to care for people at home (including in skilled 
nursing facilities) through excellence in physical symptom control, psychological support, 
spiritual care and support for caregivers.  
Symptom burden in end-of-life care 
Hospice care improves symptom control in problems prevalent at the end of life.22 Attention 
to physical symptoms is valued by patients and their families as a key goal of care. 10 There is 
a rapidly evolving evidence base from randomised controlled trials to improve symptom 
control in end of life care 23-26 yet many of these findings have not been embedded in 
practice.14 The research also highlights areas where further research is necessary.  
The burden of physical symptoms evolves in the last weeks of life. Two symptoms which 
tend to worsen as functional status predictably declines are fatigue and breathlessness.27,28 
Fatigue not reduced by rest is often the most overwhelming symptom experienced by people 
with advance cancer. It often co-exists with cachexia in this setting.29 Fatigue generates 
frustration for patients as they struggle to re-prioritise their activities in the limited time that 
they have left, while often being exhausted by relatively trivial exertion. Non-
pharmacological interventions have not been well studied in people in the last weeks of life.30 
[ref] Other than reversing causes that can cause fatigue (severe anaemia), the evidence for 
pharmacological interventions for fatigue in patients with advanced cancer is limited.31 [ref] 
Candidate medications include methylphenidate, amantadine or modafinil, but none has 
sufficient data to justify their use in routine clinical care.  
Prevalence and intensity of chronic breathlessness320 often worsen as death approaches even 
in people with no documented cardio-respiratory disease, especially in the last two to three 
weeks of life.331 The proportion of people with no breathlessness drops rapidly in the last 
weeks of life and the proportion with severe breathlessness increases despite symptomatic 
treatment. The evidence base for effectively and safely treating chronic breathlessness 
continues to improve using non-pharmacological and pharmacological interventions reflected 
in systematic reviews and meta-analyses.34,352,33 In a systematic approach to assessing and 
treating chronic breathlessness akin to the World Health Organisation (WHO) analgesic 
ladder, the most important step is to ensure that reversible causes have been adequately 
treated364 while considering non-pharmacological and subsequently pharmacological 
interventions.375 Uncontrolled breathlessness is frightening and exhausting for patients, and 
confronting for caregivers, often leaving haunting and unpleasant memories.386 Minimising  
breathlessness is therefore imperative for patients’ and families’ wellbeing.  
As function declines in the last weeks of life, the intensity and prevalence of pain may also 
decrease, perhaps reflecting how much of the pain is exacerbated with incident movement 
and subsequently experienced at rest.397 Good analgesia is often the priority for patients and 
their families above any other symptom right through until death. Evidence supports that 







access hospice.22 Late in life, immobility perversely also frequently causes pain and careful 
attention to repositioning patients regularly is a hallmark of exemplary nursing care. When 
patients no longer have the strength to reposition themselves, air mattresses can help to shift 
patients’ weight but do not replace ongoing attentive nursing care. 
Delirium is characterised by cognitive changes (especially poor concentration), perceptual 
changes (especially hallucinations) and physical changes such as disturbed sleep/wake cycles. 
One third of people admitted for inpatient care at the end of life will have prevalent delirium 
and another one third will develop incident delirium during the admission,4038 encompassing  
hypoactive and hyperactive delirium. Hypoactive delirium is under-diagnosed in people at the 
end of life, but can be as distressing for patients as hyperactive delirium.  
In a percentage of patients, reversible causes for delirium will be found, aiding them to more 
rapidly regain their cognition.41,4239,40 The first aim of managing delirium is to ensure patient 
safety, and the safety of all those around the patient. Excellent nursing care ensures that 
visual and hearing aids are in place, ongoing efforts are made to orient the person, day and 
night are differentiated, and that hydration and nutrition are attended to with regular meals 
where feeding is supervised.  
Benefits from anti-psychotics for delirium seem negligible in placebo controlled studies 
involving intensive care patients and those nearing the end of life.25,431 Delirium requires 
excellent nursing care, treating reversible precipitants and, if there is a need for safety, 
consideration of a sedative short term.  
Symptoms in the last hours of life 
For many caregivers, the person’s last hours will be remembered because of noisy respiratory 
secretions. This noise is because secretions are not being cleared effectively and is usually 
associated with the patient being deeply unconscious. The treatment of these secretions is 
largely, if not exclusively, for the benefit of the person’s family. There is no demonstrated 
intervention for preventing noisy secretions at the end of life and no pharmacological or non-
pharmacological intervention that has been shown to be of predictable benefit in changing the 
clinical course of secretions.431 
Patients rating of symptom control – the need to improve care 
There is international evidence that the quality of care for people with advanced, progressive 
illnesses must improve.15-19,453 Feedback that is independent of the individual health care 
professional/patient interaction suggests that symptom control is not as good as we anticipate, 
nor as good as patient and families expect.17,19 This reflects an under-detection by clinicians, 
clinical interventions which do not reflect best evidence, and lack of referral to inter-
disciplinary services that could provide more comprehensive support for people with more 
complex needs. 
Addressing this mismatch includes critically evaluating the quality of care for people with 
cancer at the end of life.46-5044-48 Providing timely feedback from patients and their caregivers 
to their clinicians can contribute to improved symptom control.49,5047,48 For example, patients 
filling out a symptom assessment tool immediately before clinical consultations so that 
clinicians see the results improves symptom control and is associated with better survival.5149 
Given the value placed on symptom control by patients and their caregivers, and the 
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symptom burden experienced by people with cancer at the end of life, health professionals 
need to ensure that the best available evidence underpins all clinical care. 
Hospice care 
Given the emphasis on excellent nursing care for optimal outcomes at the end of life, it is 
appropriate that hospice care has arisen from nursing and been complemented with other 
clinical disciplines more recently. Care that can support patients to be functional for as long 
as possible and simultaneously provide symptom control will deliver the best outcomes. The 
majority of care in the last year of life occurs in the community 520 and relies almost 
exclusively on the presence, capability and willingness of family and friends to take on 
caregiving roles.531 The way that caregivers are supported in their new roles is a fundamental 
of hospice care.  
When people with advanced cancer start to experience rapid functional declines, it is 
important to ensure hospice care is in place. At this time, conversations about prognosis 
should occur. The speed of deterioration in the last weeks of life is surprising to many 
clinicians who do not frequently encounter it.542 Providing realistic timeframes to patients 
and their caregivers is an important part of care in the last weeks of life. Patients need this 
information so that they are able to prioritise the things that are most important to them in the 
time remaining. 
Key competencies for all health professionals in end of life care.  
Several competencies are required for good end-of-life care. Every health professional ought 
to be able to demonstrate core end-of-life competencies including: recognising the end-of-
life; understanding of the principles of symptom control and inter-disciplinary care; patient-
centred communication and shared decision making; clinical skills in thorough bedside 
assessment; and fostering personal attributes including empathy and compassion.553 Good 
communication includes active listening, responding to emotion, communicating difficult 
information, and ascertaining the person’s values and preferences (especially for advance 
care planning). These capabilities enable health professionals to help patients and their 
families plan their end-of-life care, manage concerns and foster good interdisciplinary care. 
(There is a current generation of health professionals for whom hospice care was not part of 
their training, and for whom a specific commitment will need to be made to improve 
knowledge and skills564 - a challenge once in busy practice.575)  
Key competencies for specialist hospice care clinicians 
To complement the general clinical workforce, there is the need to have a specialist 
hospice/palliative care workforce that can provide care to patients and families with more 
complex needs. Whilst providing this more complex care, this specialist workforce is 
simultaneously continuing to generate new evidence (research) and rapidly translate it into 
practice to improve care (education, systems change).24,25,58-6156-59 Studies demonstrate that 
when high quality evidence is generated, health professionals change practice.62,630,61   
Team-based care 
Good support provided to patients and their families is intrinsically complex. It is unlikely 
that any one clinician will meet the entire hospice care needs of each patient and their family 
while the person is alive or the family’s needs after the person’s death.  Using a validated 
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palliative care needs assessment tool helps clinicians recognise when the patients or families 
require additional support from other team members or services.642 The Palliative Care Needs 
Assessment Tool (Cancer) (PC-NAT (Cancer)) has four domains: patient; caregiver 
willingness to provide care; caregiver ability to provide care; and any health professional 
issues.65 [ref] The routine use of such a tool in people with advanced cancer in an interrupted 
time series study compared to standard practice demonstrated better met informational needs 
for patients and caregivers.21 Evidence for the validity of this tool in primary care 
consultations in people with advanced cancer has been established.663  
An inter-disciplinary team approach is needed to provide patients and their families with a 
range of health professionals with whom to interact. The ability to relate to a broader group 
of people allows patients and their families to choose when and what is discussed and with 
whom. It is likely that patients will discuss different issues with different health professionals 
in the time and place that suits the patient. This means that several lines of communication 
need to be open to people in the last weeks of life.  
Given the advances that are being made in high quality evidence, it is unlikely that any one 
practitioner can be fully up to date, thus requiring a team-based, interdisciplinary approach. 
Given the breadth of patient-defined needs at the end of life, several health professionals 
working collaboratively will be essential to achieve the best possible patient outcomes.  
Interfaces between hospice and other healthcare settings 
Most people will use hospitals in the last year of life, increasing markedly in the final months 
of life 520 and in most high income countries the majority of people who die from cancer will 
do so as an inpatient. This requires an effective working relationship between hospice and 
other health services. Planning of care reduces hospitalisations and emergency department 
presentations. 67,684,65 In a retrospective consecutive cohort study of 91,561 people with 
advanced cancer in Canada, on average, people made more than two visits to the Emergency 
Department (ED) in the last six months of life, mostly due to poor symptom control.696 In a 
retrospective consecutive cohort study of 746 people with advanced cancer, timely referral to 
hospice was associated with reduced use of the ED by people with advanced cancer (31.3% 
of people who had earlier access to hospice used the ED while it increased to 52.0% of 
people who didn’t have hospice access), fewer hospital bed days and better symptom 
control.7067 These findings are reflected in a more recent retrospective study from 54,743 
people with advanced cancer where access to hospice care in the last six months of life 
reduced high- and low-acuity ED presentations.7168 Reduced costs without compromising care 
can be demonstrated,67,68,7264,65,69 although this cost-benefit was less clear after the hospice 
benefit payment was extended to nursing homes in the USA.730 Differentials in hospital 
utilisation and use of intensive care is a key driver in any measured cost differentials.74,751,72 
A dynamic and timely interface between hospice providers and inpatient services is 
increasingly being facilitated by the use of electronic information technology clinical 
platforms, ensuring better currency of clinical data as people move between places of care. 
Ensuring that both clinical teams are aware of each other’s conversations with the patient and 
family is a fundamental challenge that persists even in an era with improving electronic 
records. 





- symptoms are complex or not responding to current therapies where a brief inpatient 
admission may more rapidly bring symptoms under control;763 
- An unexpected change in clinical condition when the person had a reasonable level of 
function and wants to pursue reasonable efforts to reverse treatable pathology;  
- Care needs exceed available community services especially due to caregiver 
fatigue;774 or 
- The person in the last days or hours of life does not want to die at home.20,785   
A growing number of people live alone in our communities and is projected to rise in the 
decades ahead. The ability of someone with advanced cancer to remain at home if they live 
alone until the time of their death is very limited. If a person’s preference is to die at home, 
the greatest predictor of this occurring is the presence of a willing and able caregiver.531 
Specific issues arise in advance care planning for people without a live-in caregiver that need 
to be addressed expectantly.  
Caregiver outcomes 
Few data are available for long term caregiver outcomes with and without access to hospice. 
One large observational study comparing cohorts who did and did not access hospice care 
suggests two benefits for caregivers: informational needs were better met; and the caregiver 
had a greater ability to ‘move on’ with his/her life after the patient’s death.that caregivers 
who have access to hospice identified their informational needs were better met and after the 
death of the person, they were better able to ‘move on’ with their lives.796 A cause-and-effect 
relationship cannot be inferred, but the study provides supportive evidence from a randomly 
selected community population who identified that they had provided care for someone close 
to them with a terminal illness in the preceding five years. Studies using propensity matched 
scores for caregivers who did and did not access hospice have shown associations including 
improved survival and lower rates of depression.8077 Such data complement data on patient-
related measures such as improved symptom control.10,8178    
Conclusion 
Clinically, data support ensuring patients have the option to consider hospice as a clinical 
path when it is recognised that they have advanced cancer. Hospice provides patients with the 
potential for better quality of life, improved symptom control, and more time away from 
inpatient care.2 The majority of care falls to family and friends, and any additional support for 
them while fulfilling their role is likely to be of substantial benefit. Observational studies 
suggest measurable benefits for caregivers after the patient dies.79,80,8176,77,78 For health 
services, data support that health service utilisation is more likely to be clinically appropriate 
with fewer hospital visits, shorter lengths of stay and less time in intensive care units if 
hospice is engaged.2,7,8,53,67,741,64,71 The future research agenda needs to include larger health 
service randomised controlled trials to fully define the net effects (benefits and burdens) of 
hospice together with larger phase III studies in key symptoms where the therapeutic choices 
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